RAE-1 antibodies are monoclonal or polyclonal reagents designed to detect and study RAE-1 proteins. These antibodies are critical for understanding RAE-1's dual roles in immune activation and tumor biology. Key features include:
Target Specificity: Recognizes RAE-1 isoforms (e.g., RD-41 clone targets RAE-1δ ).
Applications: Flow cytometry, Western blotting (WB), immunohistochemistry (IHC), immunofluorescence (IF), and ELISA .
Species Reactivity: Primarily validated in mice and humans .
RAE-1 antibodies are utilized across diverse experimental contexts:
RAE-1 overexpression on MHC class I⁺ tumors (e.g., RMA lymphoma) triggers NK cell-mediated rejection in vivo, bypassing the "missing self" hypothesis .
MDSCs expressing RAE-1 activate NK cells via NKG2D, enhancing IFN-γ production and antitumor responses .
Breast Cancer: RAE-1 promotes epithelial-mesenchymal transition (EMT) by upregulating ZEB1, driving metastasis .
Colorectal Cancer: RAE-1 overexpression stabilizes spindle bipolarity, inhibits apoptosis, and induces chemoresistance .
RAE-1 ensures proper spindle formation during mitosis; its dysregulation causes chromosome instability and tumorigenesis .
Isoform Cross-Reactivity: Some antibodies (e.g., "pan-RAE-1") detect multiple isoforms, while others (e.g., RD-41) are isoform-specific .
Experimental Optimization: Titration is essential for assays like IHC, where antigen retrieval methods vary (e.g., TE buffer pH 9.0 vs. citrate buffer pH 6.0) .
Species Limitations: Most antibodies are validated for murine or human systems; cross-reactivity with other species is untested .